Cited 0 times in Scipus Cited Count

Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease

DC Field Value Language
dc.contributor.authorYou, SC-
dc.contributor.authorAn, MH-
dc.contributor.authorYoon, D-
dc.contributor.authorBan, GY-
dc.contributor.authorYang, PS-
dc.contributor.authorYu, HT-
dc.contributor.authorPark, RW-
dc.contributor.authorJoung, B-
dc.date.accessioned2019-11-13T04:27:31Z-
dc.date.available2019-11-13T04:27:31Z-
dc.date.issued2018-
dc.identifier.issn1547-5271-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/17582-
dc.description.abstractBACKGROUND: Rate-control medications are considered first-line treatment for patients with atrial fibrillation (AF). However, obstructive lung disease (OLD), a condition prevalent in those with AF, often makes it difficult to use those medications because of the lack of studies on new-onset AF in patients with OLD.
OBJECTIVE: The purpose of this study was to investigate clinical outcomes after administration of each class of rate-control medication in patients with concomitant AF and OLD (AF-OLD).
METHODS: This study used the entire database provided by the National Health Insurance Service from 2002 to 2015. Risk of all-cause mortality was compared between use of calcium channel blocker (CCB) and use of other drug classes in AF-OLD patients using Cox regression analyses after propensity score matching.
RESULTS: Among the 13,111 patients, the number of AF-OLD patients treated with a CCB, cardioselective beta-blocker (BB), nonselective BB, and digoxin was 2482, 2379, 2255, and 5995, respectively. The risk of mortality was lower with use of selective BB (hazard ratio [HR] 0.84: 95% confidence interval [CI] 0.75-0.94: P = .002) and nonselective BB (HR 0.85: 95% CI 0.77-0.95: P = .003) compared to use of CCBs. Digoxin use was related with worse survival, with marginal statistical significance (HR 1.09: 95% CI 1.00-1.18: P = .053).
CONCLUSION: Among patients with AF-OLD, rate-control treatment using selective and nonselective BB was associated with a significant reduction in mortality compared with CCB use. Further prospective randomized trials are required to confirm these findings.
-
dc.language.isoen-
dc.subject.MESHAdrenergic beta-Antagonists-
dc.subject.MESHAged-
dc.subject.MESHAnti-Arrhythmia Agents-
dc.subject.MESHAtrial Fibrillation-
dc.subject.MESHCause of Death-
dc.subject.MESHDigoxin-
dc.subject.MESHFemale-
dc.subject.MESHHeart Rate-
dc.subject.MESHHumans-
dc.subject.MESHLung Diseases, Obstructive-
dc.subject.MESHMale-
dc.subject.MESHPropensity Score-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.titleRate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease-
dc.typeArticle-
dc.identifier.pmid30509364-
dc.subject.keywordAdrenergic beta-antagonist-
dc.subject.keywordAtrial fibrillation-
dc.subject.keywordCalcium channel blocker-
dc.subject.keywordDigoxin-
dc.subject.keywordHeart rate-
dc.subject.keywordObstructive lung disease-
dc.contributor.affiliatedAuthor윤, 덕용-
dc.contributor.affiliatedAuthor박, 래웅-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.hrthm.2018.06.044-
dc.citation.titleHeart rhythm-
dc.citation.volume15-
dc.citation.number12-
dc.citation.date2018-
dc.citation.startPage1825-
dc.citation.endPage1832-
dc.identifier.bibliographicCitationHeart rhythm, 15(12). : 1825-1832, 2018-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1556-3871-
dc.relation.journalidJ015475271-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Biomedical Informatics
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse